CA2285020A1

CA2285020A1 - Novel human delta3 compositions and therapeutic and diagnostic uses therefor

Novel human delta3 compositions and therapeutic and diagnostic uses therefor Download PDF

Info

Publication number: CA2285020A1
Authority: CA; Canada
Prior art keywords: delta3; protein; amino acid; polypeptide; gene
Prior art date: 1997-04-04
Legal status : Abandoned

Application number

CA002285020A

Other languages

English (en)

French (fr)

Inventor

Sean A. Mccarthy

David P. Gearing

Current Assignee

Millennium Pharmaceuticals Inc

Original Assignee

Individual

Priority date

1997-04-04

Filing date

1998-04-06

Publication date

1998-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2285020(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-11 Priority claimed from US08/872,855 external-priority patent/US6121045A/en

1998-04-06 Application filed by Individual filed Critical Individual

1998-10-15 Publication of CA2285020A1 publication Critical patent/CA2285020A1/en

Status Abandoned legal-status Critical Current

Links

230000001225 therapeutic effect Effects 0.000 title claims description 40
241000282414 Homo sapiens Species 0.000 title description 39
239000000203 mixture Substances 0.000 title description 26
101710112748 Delta-like protein 3 Proteins 0.000 claims abstract description 709
102100036466 Delta-like protein 3 Human genes 0.000 claims abstract description 622
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 263
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 232
229920001184 polypeptide Polymers 0.000 claims abstract description 218
150000007523 nucleic acids Chemical class 0.000 claims abstract description 196
102000039446 nucleic acids Human genes 0.000 claims abstract description 180
108020004707 nucleic acids Proteins 0.000 claims abstract description 180
210000004027 cell Anatomy 0.000 claims abstract description 177
238000000034 method Methods 0.000 claims abstract description 170
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 93
230000000694 effects Effects 0.000 claims abstract description 81
201000010099 disease Diseases 0.000 claims abstract description 64
230000001594 aberrant effect Effects 0.000 claims abstract description 52
201000003225 agenesis of the corpus callosum with peripheral neuropathy Diseases 0.000 claims abstract description 39
208000012902 Nervous system disease Diseases 0.000 claims abstract description 28
208000025966 Neurological disease Diseases 0.000 claims abstract description 25
210000002889 endothelial cell Anatomy 0.000 claims abstract description 14
230000012010 growth Effects 0.000 claims abstract description 7
108090000623 proteins and genes Proteins 0.000 claims description 357
102000004169 proteins and genes Human genes 0.000 claims description 233
150000001875 compounds Chemical class 0.000 claims description 136
230000014509 gene expression Effects 0.000 claims description 90
125000003275 alpha amino acid group Chemical group 0.000 claims description 82
125000003729 nucleotide group Chemical group 0.000 claims description 80
239000002773 nucleotide Substances 0.000 claims description 79
150000001413 amino acids Chemical class 0.000 claims description 78
108700028369 Alleles Proteins 0.000 claims description 59
238000012360 testing method Methods 0.000 claims description 57
230000027455 binding Effects 0.000 claims description 52
239000000523 sample Substances 0.000 claims description 52
102000037865 fusion proteins Human genes 0.000 claims description 46
108020001507 fusion proteins Proteins 0.000 claims description 46
101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 claims description 37
108010070047 Notch Receptors Proteins 0.000 claims description 37
102000005650 Notch Receptors Human genes 0.000 claims description 34
230000003902 lesion Effects 0.000 claims description 33
239000013598 vector Substances 0.000 claims description 33
108091028043 Nucleic acid sequence Proteins 0.000 claims description 31
239000013612 plasmid Substances 0.000 claims description 23
206010028980 Neoplasm Diseases 0.000 claims description 22
230000002068 genetic effect Effects 0.000 claims description 19
230000035755 proliferation Effects 0.000 claims description 17
230000001086 cytosolic effect Effects 0.000 claims description 16
230000002401 inhibitory effect Effects 0.000 claims description 16
230000015572 biosynthetic process Effects 0.000 claims description 15
208000033808 peripheral neuropathy Diseases 0.000 claims description 15
150000003384 small molecules Chemical class 0.000 claims description 9
201000011510 cancer Diseases 0.000 claims description 8
239000008194 pharmaceutical composition Substances 0.000 claims description 8
210000000653 nervous system Anatomy 0.000 claims description 7
230000004936 stimulating effect Effects 0.000 claims description 7
239000000816 peptidomimetic Substances 0.000 claims description 6
210000000877 corpus callosum Anatomy 0.000 claims description 3
108020004711 Nucleic Acid Probes Proteins 0.000 claims 2
239000002853 nucleic acid probe Substances 0.000 claims 2
230000001363 autoimmune Effects 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
239000002254 cytotoxic agent Substances 0.000 claims 1
230000002093 peripheral effect Effects 0.000 claims 1
239000005557 antagonist Substances 0.000 abstract description 26
239000003814 drug Substances 0.000 abstract description 26
239000000556 agonist Substances 0.000 abstract description 24
230000024245 cell differentiation Effects 0.000 abstract description 16
230000004069 differentiation Effects 0.000 abstract description 16
230000002159 abnormal effect Effects 0.000 abstract description 10
230000010261 cell growth Effects 0.000 abstract description 7
238000002405 diagnostic procedure Methods 0.000 abstract description 7
208000019553 vascular disease Diseases 0.000 abstract description 5
235000018102 proteins Nutrition 0.000 description 225
102000053602 DNA Human genes 0.000 description 63
108020004414 DNA Proteins 0.000 description 63
235000001014 amino acid Nutrition 0.000 description 60
229940024606 amino acid Drugs 0.000 description 59
210000001519 tissue Anatomy 0.000 description 50
230000035772 mutation Effects 0.000 description 48
238000003556 assay Methods 0.000 description 46
108020004999 messenger RNA Proteins 0.000 description 44
108091034117 Oligonucleotide Proteins 0.000 description 43
230000000692 anti-sense effect Effects 0.000 description 42
239000012634 fragment Substances 0.000 description 39
241001465754 Metazoa Species 0.000 description 38
229920002477 rna polymer Polymers 0.000 description 38
230000001105 regulatory effect Effects 0.000 description 34
230000000295 complement effect Effects 0.000 description 29
208000035475 disorder Diseases 0.000 description 28
102000053642 Catalytic RNA Human genes 0.000 description 27
108090000994 Catalytic RNA Proteins 0.000 description 27
108091092562 ribozyme Proteins 0.000 description 27
230000003993 interaction Effects 0.000 description 25
238000001514 detection method Methods 0.000 description 24
230000006870 function Effects 0.000 description 23
238000009396 hybridization Methods 0.000 description 23
101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 22
-1 repeat 1 Chemical group 0.000 description 22
239000013604 expression vector Substances 0.000 description 21
238000003776 cleavage reaction Methods 0.000 description 20
230000009261 transgenic effect Effects 0.000 description 20
239000003795 chemical substances by application Substances 0.000 description 19
230000007017 scission Effects 0.000 description 19
241000699666 Mus <mouse, genus> Species 0.000 description 18
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
238000011161 development Methods 0.000 description 18
230000018109 developmental process Effects 0.000 description 18
239000000047 product Substances 0.000 description 18
230000004071 biological effect Effects 0.000 description 17
108020003175 receptors Proteins 0.000 description 17
102000004190 Enzymes Human genes 0.000 description 16
108090000790 Enzymes Proteins 0.000 description 16
101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 16
241000269370 Xenopus <genus> Species 0.000 description 16
229940088598 enzyme Drugs 0.000 description 16
238000001727 in vivo Methods 0.000 description 16
102000005962 receptors Human genes 0.000 description 16
108091026890 Coding region Proteins 0.000 description 15
230000004663 cell proliferation Effects 0.000 description 15
238000003199 nucleic acid amplification method Methods 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
238000012216 screening Methods 0.000 description 15
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 14
230000005913 Notch signaling pathway Effects 0.000 description 14
241000700159 Rattus Species 0.000 description 14
230000003321 amplification Effects 0.000 description 14
230000019491 signal transduction Effects 0.000 description 14
238000011144 upstream manufacturing Methods 0.000 description 14
101150014361 Delta gene Proteins 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
238000000338 in vitro Methods 0.000 description 13
239000003446 ligand Substances 0.000 description 13
238000003752 polymerase chain reaction Methods 0.000 description 13
238000013518 transcription Methods 0.000 description 13
230000035897 transcription Effects 0.000 description 13
230000002103 transcriptional effect Effects 0.000 description 13
108010076504 Protein Sorting Signals Proteins 0.000 description 12
230000001413 cellular effect Effects 0.000 description 12
238000013519 translation Methods 0.000 description 12
241000252212 Danio rerio Species 0.000 description 11
230000004075 alteration Effects 0.000 description 11
230000000890 antigenic effect Effects 0.000 description 11
239000000074 antisense oligonucleotide Substances 0.000 description 11
238000012230 antisense oligonucleotides Methods 0.000 description 11
239000002299 complementary DNA Substances 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
238000012217 deletion Methods 0.000 description 10
230000037430 deletion Effects 0.000 description 10
238000003018 immunoassay Methods 0.000 description 10
230000002163 immunogen Effects 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
230000004044 response Effects 0.000 description 10
238000006467 substitution reaction Methods 0.000 description 10
241000287828 Gallus gallus Species 0.000 description 9
108020004511 Recombinant DNA Proteins 0.000 description 9
208000006011 Stroke Diseases 0.000 description 9
238000004113 cell culture Methods 0.000 description 9
235000013330 chicken meat Nutrition 0.000 description 9
230000004048 modification Effects 0.000 description 9
238000012986 modification Methods 0.000 description 9
230000001613 neoplastic effect Effects 0.000 description 9
230000008685 targeting Effects 0.000 description 9
238000011282 treatment Methods 0.000 description 9
108700019146 Transgenes Proteins 0.000 description 8
230000003042 antagnostic effect Effects 0.000 description 8
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000013459 approach Methods 0.000 description 8
210000003169 central nervous system Anatomy 0.000 description 8
210000003527 eukaryotic cell Anatomy 0.000 description 8
238000001476 gene delivery Methods 0.000 description 8
206010020718 hyperplasia Diseases 0.000 description 8
239000000126 substance Substances 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
208000024827 Alzheimer disease Diseases 0.000 description 7
108020005544 Antisense RNA Proteins 0.000 description 7
208000010482 CADASIL Diseases 0.000 description 7
102000014914 Carrier Proteins Human genes 0.000 description 7
208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 7
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
239000004793 Polystyrene Substances 0.000 description 7
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
238000007792 addition Methods 0.000 description 7
108091008324 binding proteins Proteins 0.000 description 7
239000003184 complementary RNA Substances 0.000 description 7
108700041286 delta Proteins 0.000 description 7
230000004927 fusion Effects 0.000 description 7
230000002390 hyperplastic effect Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
230000003834 intracellular effect Effects 0.000 description 7
239000000463 material Substances 0.000 description 7
230000002062 proliferating effect Effects 0.000 description 7
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 7
108020005187 Oligonucleotide Probes Proteins 0.000 description 6
241000251539 Vertebrata <Metazoa> Species 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000011324 bead Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
238000009472 formulation Methods 0.000 description 6
238000011065 in-situ storage Methods 0.000 description 6
230000037230 mobility Effects 0.000 description 6
210000002569 neuron Anatomy 0.000 description 6
201000001119 neuropathy Diseases 0.000 description 6
230000007823 neuropathy Effects 0.000 description 6
239000002751 oligonucleotide probe Substances 0.000 description 6
230000000750 progressive effect Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
230000010076 replication Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
206010012289 Dementia Diseases 0.000 description 5
101800003838 Epidermal growth factor Proteins 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
241000282412 Homo Species 0.000 description 5
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 5
101710181812 Methionine aminopeptidase Proteins 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
101710163270 Nuclease Proteins 0.000 description 5
108010036908 Presenilin-2 Proteins 0.000 description 5
102000012419 Presenilin-2 Human genes 0.000 description 5
102100033237 Pro-epidermal growth factor Human genes 0.000 description 5
108700008625 Reporter Genes Proteins 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
239000004473 Threonine Substances 0.000 description 5
230000001270 agonistic effect Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
230000008859 change Effects 0.000 description 5
230000002759 chromosomal effect Effects 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
238000002742 combinatorial mutagenesis Methods 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
230000007547 defect Effects 0.000 description 5
230000007850 degeneration Effects 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
230000002255 enzymatic effect Effects 0.000 description 5
229940116977 epidermal growth factor Drugs 0.000 description 5
239000000499 gel Substances 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
238000002372 labelling Methods 0.000 description 5
229920002521 macromolecule Polymers 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
229910052751 metal Inorganic materials 0.000 description 5
239000002184 metal Substances 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
208000015122 neurodegenerative disease Diseases 0.000 description 5
230000000626 neurodegenerative effect Effects 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
210000001236 prokaryotic cell Anatomy 0.000 description 5
238000012163 sequencing technique Methods 0.000 description 5
230000011664 signaling Effects 0.000 description 5
239000007790 solid phase Substances 0.000 description 5
238000001890 transfection Methods 0.000 description 5
210000005166 vasculature Anatomy 0.000 description 5
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
108010070675 Glutathione transferase Proteins 0.000 description 4
102000005720 Glutathione transferase Human genes 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
108010036933 Presenilin-1 Proteins 0.000 description 4
102000012412 Presenilin-1 Human genes 0.000 description 4
102000018120 Recombinases Human genes 0.000 description 4
BNGDYRRHRGOPHX-IFFSRLJSSA-N Thr-Glu-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O BNGDYRRHRGOPHX-IFFSRLJSSA-N 0.000 description 4
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000005856 abnormality Effects 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
238000010171 animal model Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
210000001072 colon Anatomy 0.000 description 4
230000009918 complex formation Effects 0.000 description 4
230000007423 decrease Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000007877 drug screening Methods 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
210000003917 human chromosome Anatomy 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
229930182817 methionine Natural products 0.000 description 4
210000003061 neural cell Anatomy 0.000 description 4
230000004481 post-translational protein modification Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
241000894007 species Species 0.000 description 4
230000017423 tissue regeneration Effects 0.000 description 4
108020005065 3' Flanking Region Proteins 0.000 description 3
108020005029 5' Flanking Region Proteins 0.000 description 3
108020004774 Alkaline Phosphatase Proteins 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 3
206010059245 Angiopathy Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
108060001084 Luciferase Proteins 0.000 description 3
208000029726 Neurodevelopmental disease Diseases 0.000 description 3
108010029756 Notch3 Receptor Proteins 0.000 description 3
102000001760 Notch3 Receptor Human genes 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108010091086 Recombinases Proteins 0.000 description 3
108010083644 Ribonucleases Proteins 0.000 description 3
102000006382 Ribonucleases Human genes 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
241000251131 Sphyrna Species 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
108700041965 Xenopus PSMB6 Proteins 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000003491 array Methods 0.000 description 3
229940009098 aspartate Drugs 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000003197 catalytic effect Effects 0.000 description 3
230000030833 cell death Effects 0.000 description 3
230000033026 cell fate determination Effects 0.000 description 3
239000003593 chromogenic compound Substances 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
238000013461 design Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000012636 effector Substances 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
229930195712 glutamate Natural products 0.000 description 3
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
230000006882 induction of apoptosis Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
230000023886 lateral inhibition Effects 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000004770 neurodegeneration Effects 0.000 description 3
230000004766 neurogenesis Effects 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
102000040430 polynucleotide Human genes 0.000 description 3
108091033319 polynucleotide Proteins 0.000 description 3
239000002157 polynucleotide Substances 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000001855 preneoplastic effect Effects 0.000 description 3
201000002241 progressive bulbar palsy Diseases 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
108091006106 transcriptional activators Proteins 0.000 description 3
238000012546 transfer Methods 0.000 description 3
108091005703 transmembrane proteins Proteins 0.000 description 3
102000035160 transmembrane proteins Human genes 0.000 description 3
230000001960 triggered effect Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
239000004474 valine Substances 0.000 description 3
108700026220 vif Genes Proteins 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
108020004491 Antisense DNA Proteins 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000271566 Aves Species 0.000 description 2
241000701822 Bovine papillomavirus Species 0.000 description 2
108090000565 Capsid Proteins Proteins 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
102100023321 Ceruloplasmin Human genes 0.000 description 2
208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
101710177611 DNA polymerase II large subunit Proteins 0.000 description 2
101710184669 DNA polymerase II small subunit Proteins 0.000 description 2
206010059866 Drug resistance Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102000012545 EGF-like domains Human genes 0.000 description 2
108050002150 EGF-like domains Proteins 0.000 description 2
102100029727 Enteropeptidase Human genes 0.000 description 2
108010013369 Enteropeptidase Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108091027305 Heteroduplex Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
208000023105 Huntington disease Diseases 0.000 description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102000004195 Isomerases Human genes 0.000 description 2
108090000769 Isomerases Proteins 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000034800 Leukoencephalopathies Diseases 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
238000000636 Northern blotting Methods 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
241000283984 Rodentia Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
208000010112 Spinocerebellar Degenerations Diseases 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
201000004810 Vascular dementia Diseases 0.000 description 2
108010037096 Xenopus Proteins Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
230000003466 anti-cipated effect Effects 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000003816 antisense DNA Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
230000003376 axonal effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000000423 cell based assay Methods 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000004700 cellular uptake Effects 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
210000002987 choroid plexus Anatomy 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000008711 chromosomal rearrangement Effects 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
238000004590 computer program Methods 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
238000013399 early diagnosis Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000002616 endonucleolytic effect Effects 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
230000010005 growth-factor like effect Effects 0.000 description 2
210000002216 heart Anatomy 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
238000012203 high throughput assay Methods 0.000 description 2
238000002744 homologous recombination Methods 0.000 description 2
230000006801 homologous recombination Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000005304 joining Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
201000010901 lateral sclerosis Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004020 luminiscence type Methods 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000036244 malformation Effects 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
210000003716 mesoderm Anatomy 0.000 description 2
230000011987 methylation Effects 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
230000033607 mismatch repair Effects 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
208000005264 motor neuron disease Diseases 0.000 description 2
230000001272 neurogenic effect Effects 0.000 description 2
230000004031 neuronal differentiation Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
229910000489 osmium tetroxide Inorganic materials 0.000 description 2
239000012285 osmium tetroxide Substances 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
238000000059 patterning Methods 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
208000027232 peripheral nervous system disease Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
210000002826 placenta Anatomy 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
102000054765 polymorphisms of proteins Human genes 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000002243 primary neuron Anatomy 0.000 description 2
230000008569 process Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000004850 protein–protein interaction Effects 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
150000003230 pyrimidines Chemical class 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000005215 recombination Methods 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
125000002652 ribonucleotide group Chemical group 0.000 description 2
238000002864 sequence alignment Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000002027 skeletal muscle Anatomy 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001541 thymus gland Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
102000027257 transmembrane receptors Human genes 0.000 description 2
108091008578 transmembrane receptors Proteins 0.000 description 2
230000032258 transport Effects 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
210000002845 virion Anatomy 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 description 1
SGAKLDIYNFXTCK-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)methylamino]acetic acid Chemical compound OC(=O)CNCC1=CNC(=O)NC1=O SGAKLDIYNFXTCK-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 description 1
WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
VKLFQTYNHLDMDP-PNHWDRBUSA-N 5-carboxymethylaminomethyl-2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C(CNCC(O)=O)=C1 VKLFQTYNHLDMDP-PNHWDRBUSA-N 0.000 description 1
ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
XTPUXCVIDQFHIT-UHFFFAOYSA-N 8-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(N)=C2NC(CCC(C)=C)=NC2=N1 XTPUXCVIDQFHIT-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
108010022752 Acetylcholinesterase Proteins 0.000 description 1
102000012440 Acetylcholinesterase Human genes 0.000 description 1
208000005452 Acute intermittent porphyria Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
108010000239 Aequorin Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
241001136792 Alle Species 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
240000000662 Anethum graveolens Species 0.000 description 1
108010049777 Ankyrins Proteins 0.000 description 1
102000008102 Ankyrins Human genes 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
206010006542 Bulbar palsy Diseases 0.000 description 1
241000244203 Caenorhabditis elegans Species 0.000 description 1
101100379376 Caenorhabditis elegans apx-1 gene Proteins 0.000 description 1
101100510615 Caenorhabditis elegans lag-2 gene Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000035336 Corpus callosum agenesis-neuronopathy syndrome Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
108010051219 Cre recombinase Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000938605 Crocodylia Species 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
108020001738 DNA Glycosylase Proteins 0.000 description 1
102000028381 DNA glycosylase Human genes 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
208000012239 Developmental disease Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
108700007800 Drosophila N Proteins 0.000 description 1
108010035533 Drosophila Proteins Proteins 0.000 description 1
108700039964 Duplicate Genes Proteins 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010093099 Endoribonucleases Proteins 0.000 description 1
102000002494 Endoribonucleases Human genes 0.000 description 1
241000792859 Enema Species 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
208000036566 Erythroleukaemia Diseases 0.000 description 1
208000000461 Esophageal Neoplasms Diseases 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
108010046276 FLP recombinase Proteins 0.000 description 1
241000282324 Felis Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
102100022624 Glucoamylase Human genes 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
241000696272 Gull adenovirus Species 0.000 description 1
108090001102 Hammerhead ribozyme Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 description 1
101000802053 Homo sapiens THUMP domain-containing protein 1 Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
241000272168 Laridae Species 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
206010024305 Leukaemia monocytic Diseases 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
108010047357 Luminescent Proteins Proteins 0.000 description 1
102000006830 Luminescent Proteins Human genes 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
102000013460 Malate Dehydrogenase Human genes 0.000 description 1
108010026217 Malate Dehydrogenase Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
206010054949 Metaplasia Diseases 0.000 description 1
108010059724 Micrococcal Nuclease Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
108090000143 Mouse Proteins Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
206010028570 Myelopathy Diseases 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000001756 Notch2 Receptor Human genes 0.000 description 1
108010029751 Notch2 Receptor Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108010053210 Phycocyanin Proteins 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
206010036182 Porphyria acute Diseases 0.000 description 1
208000006994 Precancerous Conditions Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
208000032319 Primary lateral sclerosis Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
101710147134 Putative transposase for insertion sequence element IS986/IS6110 Proteins 0.000 description 1
108010066717 Q beta Replicase Proteins 0.000 description 1
108090000244 Rat Proteins Proteins 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
108700005078 Synthetic Genes Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
241000248384 Tetrahymena thermophila Species 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
208000026062 Tissue disease Diseases 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
101710195626 Transcriptional activator protein Proteins 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
101710099762 Uncharacterized protein in sodM 3'region Proteins 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
206010046298 Upper motor neurone lesion Diseases 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
208000026481 Werdnig-Hoffmann disease Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
108010067041 Zebrafish Proteins Proteins 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229940022698 acetylcholinesterase Drugs 0.000 description 1
DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
208000021841 acute erythroid leukemia Diseases 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
108010004469 allophycocyanin Proteins 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
210000001776 amniocyte Anatomy 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
229940025131 amylases Drugs 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
210000002403 aortic endothelial cell Anatomy 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000010420 art technique Methods 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
238000002820 assay format Methods 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
238000005415 bioluminescence Methods 0.000 description 1
230000029918 bioluminescence Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000033081 cell fate specification Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
210000004671 cell-free system Anatomy 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000012707 chemical precursor Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
210000004252 chorionic villi Anatomy 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
201000010989 colorectal carcinoma Diseases 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000009402 cross-breeding Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
230000029087 digestion Effects 0.000 description 1
RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000008011 embryonic death Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
230000003090 exacerbative effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
230000000893 fibroproliferative effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
125000001965 gamma-lactamyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
208000025750 heavy chain disease Diseases 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012188 high-throughput screening assay Methods 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000008102 immune modulation Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
239000012212 insulator Substances 0.000 description 1
239000000138 intercalating agent Substances 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000007154 intracellular accumulation Effects 0.000 description 1
230000010189 intracellular transport Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
230000007654 ischemic lesion Effects 0.000 description 1
229910052747 lanthanoid Inorganic materials 0.000 description 1
150000002602 lanthanoids Chemical class 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
108010082117 matrigel Proteins 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
230000015689 metaplastic ossification Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
210000004925 microvascular endothelial cell Anatomy 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000006894 monocytic leukemia Diseases 0.000 description 1
230000007659 motor function Effects 0.000 description 1
210000002161 motor neuron Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
238000002610 neuroimaging Methods 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000001821 nucleic acid purification Methods 0.000 description 1
238000011330 nucleic acid test Methods 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
208000030212 nutrition disease Diseases 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000005642 phosphothioate group Chemical group 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000009598 prenatal testing Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
201000008752 progressive muscular atrophy Diseases 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000031877 prophase Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
230000004952 protein activity Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
229910052761 rare earth metal Inorganic materials 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000002271 resection Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
208000017779 riboflavin transporter deficiency Diseases 0.000 description 1
238000005070 sampling Methods 0.000 description 1
210000004116 schwann cell Anatomy 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
101150112575 sel-12 gene Proteins 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
230000037152 sensory function Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000012453 solvate Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
210000002023 somite Anatomy 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000002739 subcortical effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000016853 telophase Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012549 training Methods 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
238000003160 two-hybrid assay Methods 0.000 description 1
238000010396 two-hybrid screening Methods 0.000 description 1
208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000010246 ultrastructural analysis Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000277 virosome Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
WCNMEQDMUYVWMJ-JPZHCBQBSA-N wybutoxosine Chemical compound C1=NC=2C(=O)N3C(CC([C@H](NC(=O)OC)C(=O)OC)OO)=C(C)N=C3N(C)C=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WCNMEQDMUYVWMJ-JPZHCBQBSA-N 0.000 description 1
238000003158 yeast two-hybrid assay Methods 0.000 description 1